Company Overview and News
KUALA LUMPUR (Sept 25): The FBM KLCI pared some of its loss at midday break today, against a backdrop of struggling regional markets.
HLFBF BRDBF 7036 1082 5681 6432 BATS 4162 7374 5256 5199 5210 1783 5029 3867 SGPBY 6888 AXXTF 5827 1902 HIPEF GEBHF 3719
KUALA LUMPUR (Sep 20): Based on corporate announcements and news flow today, stocks in focus for Friday (Sep 21) may include the following: Scientex Bhd, Malaysia Smelting Corp Bhd, Eco World International Bhd, Pos Malaysia Bhd, AWC Bhd, Wong Engineering Corp Bhd, Dufu Technology Corp Bhd, Selangor Properties Bhd, SCGM Bhd and Pan Malaysia Corp Bhd.
4634 1783 SGPBY 7233
KUALA LUMPUR (Sept 20): Selangor Properties Bhd's net profit surged 70.2% to RM33.2 million in the third financial quarter ended July 31, 2018 (3QFY18) from RM19.51 million a year ago, mainly due to higher foreign exchange (forex) gain of RM16.3 million.
1783 SGPBY BSMAF 1818
KUALA LUMPUR (Sept 18): The FBM KLCI fell 0.66% at midday break, as new tariffs announced by Washington on Chinese imports rattled regional markets.
HLFBF 7052 MLYNF 8621 9679 BATS 4162 2089 1783 1023 5225 IHHHF PNAGF HRGHY MLYBY UPBMF 1082 5681 5168 6033 7123 CIMDF 5238 1155 PNADF SGPBY 0026 Q0F
Chook retired as executive chairman of the property development company in December 2017, according to a Dec 27 Bursa Malaysia filing. On the same day, the company told Bursa that Wen Chiu Chi, 61, the third among Chook’s four children, was assuming the position of executive chairman. He was previously the managing director. SelProp is one of the oldest property companies on Bursa Malaysia.
1783 SGPBY BSMAF 1818
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.43% at the midday break today as index-linked blue chip stocks lifted the local benchmark index.
HLFBF 7062 7052 7060 7036 1082 5681 BATS 4162 5014 6033 4634 1783 5029 PNADF 5347 5016 1589 SGPBY TNABY 2739 MYPRY TNABF PNAGF
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.39% at mid-morning today, lifted by index-linked blue chips and tracking the steady regional markets.
7052 7036 5681 BATS 4162 3034 1481 5014 6033 0152 1783 PNADF 5225 SGPBY 5209 2216 2739 MYPRY Q0F IHHHF PNAGF
Selangor Properties Bhd (June 27, RM4.14) Maintain hold with a lower target price (TP) of RM4.40: Selangor Properties Bhd’s first half ended April 30, 2018 (1HFY18) core net profit came in below expectations at 40% of our full-year estimate and 42% of the Bloomberg consensus number.
KUALA LUMPUR (June 26): Based on corporate announcements and news flow today, stocks in focus for Wednesday (June 27) may include the following: T7 Global Bhd, MSM Malaysia Holdings Bhd, Selangor Properties Bhd, APFT Bhd, Poh Huat, Alam Maritim Resources Bhd, Berjaya Media Bhd and Sunway Bhd.
1783 5115 SGPBY 6025 5202
KUALA LUMPUR (June 25): Selangor Properties Bhd’s net profit for the second quarter ended April 30, 2018 (2QFY18) contracted by 22.9% to RM6.63 million from RM8.6 million in the same period a year ago, which was dragged by fair value loss of its investments overseas but the amount was mitigated by a narrower unrealised foreign exchange loss.
1783 SGPBY BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...